Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tdon1229on Jun 06, 2024 8:27pm
220 Views
Post# 36076657

RE:RE:Questions 3 and 4

RE:RE:Questions 3 and 4Pandora,

The regulators didn't change anything here.  Theralase botched the treatment of their first 12 patients (under Dr. Jewett), which resulted in the need to adjust their sample size and the numbers of successful treatments needed to obtain the results necessary to address the size of market to which the results would apply.  Anyone with any statistical sampling experience knows this.
 
The charts can be found on the FDA clinical trials site. I looked at them back in 2014 when I first became interested in the company, but I can't point you to them today.  Of note, however, is the fact that the Study II results are significantly less than the small number reults from the Phase 1b trial.  If they were still having success with 2 of every 3 patients, then I suspect we'd be further advanced by now, but our numbers haven't been thst good.

Regards,
tdon1229
<< Previous
Bullboard Posts
Next >>